Navigation Links
Investigational urine test can predict high-risk prostate cancer in men who chose 'watchful waiting'
Date:2/2/2012

SEATTLE Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease. Ultimately, these markers may lead to the development of a urine test that could complement prostate biopsy for predicting disease aggressiveness and progression.

Study principal investigator Daniel Lin, M.D., an associate member of the Hutchinson Center's Public Health Sciences Division, will present these findings today at the 2012 Genitourinary Cancers Symposium of the American Society of Clinical Oncology in San Francisco.

"Prostate biopsies are invasive and don't always pick up all of the cancer. Post-digital-rectal exam urine collection is much less invasive. If a urine-based diagnostic test could be developed that could help predict aggressive disease or disease progression, that would be ideal," said Lin, who is also an associate professor and chief of urologic oncology at the University of Washington Department of Urology.

Lin leads a nationwide consortium of eight institutions called the Canary Prostate Active Surveillance Study, an endeavor dedicated to identifying and validating biomarkers of high-risk prostate cancer.

Because many prostate cancers are slow growing and never become life threatening, many men with early stage prostate cancer choose active surveillance delaying treatment while closely monitoring to see whether the cancer progresses.

Two urine-based biomarkers were found to correlate with indicators of aggressive disease: tumor volume (the number of biopsy samples that contain cancer) and Gleason score (predicting the aggressiveness of cancer by how it looks under a microscope). The markers that mirrored these correlates of disease aggressiveness were:

  • PCA3 a non-coding RNA that is found at high levels in prostate cancer relative to benign prostate cells; and
  • TMPRSS2-ERG the fusion of TMPRSS2, a gene that is regulated by androgens, with ERG, an oncogene. These genetic rearrangements are found in about half of all prostate cancers and are thought to play a role in prostate cancer development.

The findings were based on an interim analysis of data collected from 401 men who opted for active surveillance of their cancer. The study compared biomarker performance to clinical data collected at the time of study entry. Ultimately, the study aims to enroll 1,000 men and follow them for at least five years.

"The ultimate goal is that men on active surveillance could use a test based on these biomarkers or others to complement biopsy and PSA data to indicate or rule out the presence of an undetected aggressive cancer or future development of aggressive cancer," said Lin, who cautioned that these initial results, while promising, need to be confirmed in a larger study that would evaluate changes in these urine biomarkers over time, along with correlation to disease progression during active surveillance. Lin further noted that neither PCA3 nor TMPRSS2-ERG are FDA-approved for prostate cancer detection and that their use in active surveillance is investigational.
'/>"/>

Contact: Kristen Lidke Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
2. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
3. New investigational compound targets pancreatic cancer cells
4. Investigational eye treatment: Corneal collagen crosslinking research study
5. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
6. Incisionless surgery now available as an investigational treatment for esophageal disorder
7. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
8. Urine test for kidney cancer a step closer to development
9. Moving Closer to a Urine Test for Colon Cancer
10. Autism finding could lead to simple urine test for the condition
11. Color, Odor Changes in Urine Usually -- But Not Always -- Harmless, Reports Harvard Women's Health Watch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2016)... ... 2016 , ... The 31st annual iaedp (International Association of ... This year’s conference event will continue the Symposium’s reputation for presenting the latest ... place March 22 - 26 at the Green Valley Resort and Spa in ...
(Date:12/10/2016)... ... December 09, 2016 , ... Even ... rates have increased greatly in recent years. This can be attributed to the ... progress hasn’t been equally distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast ...
(Date:12/10/2016)... ... December 10, 2016 , ... ... Santa are all sources of external stimuli that can put a great deal ... pressure to spread holiday cheer through gifts, food and festive gatherings can lead ...
(Date:12/10/2016)... ... December 10, 2016 , ... "TransPanel Volume 2 is a package of fading ... Austin - CEO of Pixel Film Studios. , TransPanel Volume 2 is a ... This set of versatile transitions features presets with up to 4 panels with complementary ...
(Date:12/10/2016)... ... December 10, 2016 , ... The Pennsylvania Athletic ... joined forces with other healthcare organizations to promote diabetes education at the World ... featured a variety of speakers from around the Commonwealth of Pennsylvania. Speakers ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016  Nevro Corp. (NYSE: NVRO ), ... evidence-based solutions for the treatment of chronic pain, today ... has filed a lawsuit for patent infringement.  The lawsuit, ... District of Delaware , alleges that ... to stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... 2016 MSD, a nationally recognized supplier of ... alternate site health care facilities, announced today that it ... ("First Choice"), a privately held national distributor of medical ... home health segments. We would like to welcome First ... compelling transaction will deliver significant and immediate value to ...
(Date:12/9/2016)... December 9, 2016 External ... Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators ... Cardioverter Defibrillators The global defibrillators ... CAGR of 5.3% from 2016-2020 and CAGR of ... grow at a CAGR of 5.2% from 2016 ...
Breaking Medicine Technology: